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Abstract
Recent studies in human fibroblasts have provided a new general paradigm of tumor suppression according to which
oncogenic signaling produces DNA damage and this, in turn, results in ATM/p53-dependent cellular senescence. Here, we
have tested this model in a variety of murine experimental systems. Overexpression of oncogenic Ras in murine fibroblasts
efficiently induced senescence but this occurred in the absence of detectable DNA damage signaling, thus suggesting a
fundamental difference between human and murine cells. Moreover, lung adenomas initiated by endogenous levels of
oncogenic K-Ras presented abundant senescent cells, but undetectable DNA damage signaling. Accordingly, K-Ras-driven
adenomas were also senescent in Atm-null mice, and the tumorigenic progression of these lesions was only modestly
accelerated by Atm-deficiency. Finally, we have examined chemically-induced fibrosarcomas, which possess a persistently
activated DNA damage response and are highly sensitive to the activity of p53. We found that the absence of Atm favored
genomic instability in the resulting tumors, but did not affect the persistent DNA damage response and did not impair p53-
dependent tumor suppression. All together, we conclude that oncogene-induced senescence in mice may occur in the
absence of a detectable DNA damage response. Regarding murine Atm, our data suggest that it plays a minor role in
oncogene-induced senescence or in p53-dependent tumor suppression, being its tumor suppressive activity probably
limited to the maintenance of genomic stability.
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Introduction
ATM plays an important role in tumor suppression as indicated
by the in vivo consequences of ATM deficiency both in human and
mice. In particular, genetic deficiency of ATM in humans is
responsible for the ataxia-telangiectasia syndrome characterized
by a high susceptibility to both DNA damage and cancer [1,2].
Mice genetically deficient in Atm present early onset of thymic
lymphomas [3–5], and enhanced susceptibility to a variety of
experimentally induced cancers, such as, mammary tumors, skin
tumors, B-cell lymphomas, intestinal tumors, and others [6–13].
At a molecular level, ATM is thought to contribute to cancer
protection through two main mechanisms. On one hand, ATM
acts locally at the sites of double-strand DNA breaks promoting
repair [14]; and, on the other hand, ATM activates p53, directly
or through its downstream effector kinase CHK2, promoting p53-
dependent responses, such as transient cell cycle arrest, senescence
or apoptosis [15,16]. Each of the above-mentioned activities of
ATM, namely, DNA repair and p53 activation, could contribute
independently to tumor suppression. The activation of p53 by
ATM has gained great relevance lately as a general tumor
suppressive mechanism after the proposal of a paradigm meant to
apply to the majority of cancers [17,18]. According to this model,
oncogenic signaling in emerging tumor cells induces per se sufficient
DNA damage to trigger p53-dependent oncogene-induced
senescence. This model is based on two main sets of evidences.
First, a variety of human tumors (including bladder, lung, breast
and colon tumors, as well as melanoma) at their earliest detectable
stages present molecular markers indicative of an ongoing DNA
damage response, including phosphorylated ATM [19,20].
Second, inactivation of individual components of the DNA
damage response, such as ATM, in cultured human fibroblasts
eliminates oncogene-induced senescence and renders these cells
permissive to oncogene-driven proliferation [21–23].
Previous work on murine models has put forward an alternative
model to explain oncogene-induced p53 activation, being its main
features that it is independent of DNA damage and that it places
Arf as the critical sensor of oncogenic signaling that mediates p53
activation [24,25]. This model is well supported by in vivo genetic
evidence in mouse cancer models. For example, Arf is essential for
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p53-mediated tumor suppression in lymphomas and sarcomas
[27,28], and for oncogene-induced senescence during mammary
tumorigenesis [29,30]. Conceivably, this Arf-based model operat-
ing during murine tumorigenesis could coexist with an Atm-based
model similar to the one proposed in human tumorigenesis. To
test this possibility, we have examined genetically in mice the role
of Atm in oncogene-induced senescence and p53-dependent
tumor suppression. For this, we have used experimental systems
that are well suited to study oncogene-induced senescence and
p53-dependent tumor suppression. In this regard, it is important to
clarify that our experiments are not designed to address the well-
established role of Atm in tumor suppression through the
maintenance of genomic stability by DNA repair.
Results
Oncogenic signaling by Ras does not activate Atm in
mouse fibroblasts
It has been firmly established in human fibroblasts that
oncogenic Ras triggers DNA damage and activation of ATM
[21–23]. To test this in murine fibroblasts, we overexpressed
oncogenic H-Ras by retroviral transduction in wild-type primary
mouse embryo fibroblasts (MEFs) and we also activated with 4-
hydroxy-tamoxifen (OHT) an inducible endogenous allele of
oncogenic K-Ras [31]. In the case of overexpressed oncogenic H-
Ras, cells were analyzed 6 days post-infection when, as expected,
cells had a clear senescent morphology. In the case of endogenous
oncogenic K-Ras, cells continued proliferating, as previously
reported [31] and in agreement with the concept that oncogenic
signaling must reach a certain threshold before triggering
senescence [29]. Interestingly, neither endogenous nor ectopic
Ras signaling were able to activate a DNA damage response as
judged by the levels of phosphorylated Atm, Chk1 or H2AX
(Fig. 1A). To exclude the possibility that DNA damage signaling
could occur in a small subpopulation of Ras-expressing MEFs, we
used a sensitive automated immunofluorescence method that
allows quantifying the signal intensity of phosphorylated-H2AX
(cH2AX) in individual nuclei. Again, senescent cells overexpress-
ing oncogenic H-Ras did not present evidence of an ongoing DNA
damage response, not even in a minority of cells (Fig. 1B). These
results suggest that murine fibroblasts undergo Ras-triggered
oncogene-induced senescence in the absence of detectable DNA
damage signaling. This implies a fundamental difference between
human and murine fibroblasts with regard to their susceptibility to
activate DNA damage signaling secondary to oncogenic signaling
by Ras.
Figure 1. Lack of evidence for DNA damage signaling and
limited role of Atm in Ras-induced senescence in murine
fibroblasts. A. Immunoblots illustrating the phosphorylation status of
Atm, Chk1 and H2AX under different conditions: infection of early
passage primary MEFs with an empty vector or with H-RasV12
expressing retrovirus (analyzed 6 days post-selection when cells were
morphologically senescent), activation of an endogenous K-RasV12
allele with 4-hydroxy-tamoxifen (OHT), and finally controls of DNA
damage by replicative stress using hydroxyurea (HU 1 mM, 3 hrs) and
by DNA breaks using ionizing radiation (IR 3 Gy, 45 min). B.
Quantitative immunofluorescence of cH2AX in single cells from the
same populations analysed in part A using high-throughput microsco-
py. The average intensity of the population is indicated with a bar. Note
that upon replicative stress (HU) only the fraction of cells in S-phase
activate the DDR, while upon irradiation (IR) the entire population
activates the DDR. C. Immunoblots of the indicated proteins 6 days
after selection of cells retrovirally transduced with H-RasV12.
doi:10.1371/journal.pone.0005475.g001
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high levels of reactive oxygen species and DNA damage [32,33],
thus precluding an analysis of oncogene-induced senescence.
Therefore, we restricted our analysis to the ability of oncogenic H-
Ras to activate p53 in the absence of Atm. Interestingly, both Arf
and p53 levels were increased in Atm-null MEFs upon overex-
pression of oncogenic H-Ras, in a manner indistinguishable from
wild-type MEFs (Fig. 1C). Moreover, Atm-null MEFs were not
permissive to H-RasV12-driven proliferation, either alone or in
combination with the cooperating oncoprotein E1a (Supplemen-
tary Fig. S1). Although, as mentioned above, the lack of
permissiveness to oncogene-driven proliferation could be due in
part to the intrinsic premature senescence of Atm-null MEFs.
Together, these results indicate that, in murine fibroblasts,
oncogenic Ras signaling activates p53 independently of Atm.
Atm is not necessary for senescence in K-RasV12-driven
lung adenomas
Lung tumorigenesis induced by endogenous oncogenic K-Ras
alleles faithfully recapitulates human lung adenocarcinoma [34],
and presents two characteristics of relevance for this study,
namely, tumorigenesis is suppressed by p53 [35,36] and it is
accompanied by a readily detectable senescence response at the
pre-malignant tumor stages [37]. Therefore, this is a well-suited
cancer model to evaluate in vivo the proposed role of Atm as a
general barrier to cancer, including lung cancer [19,20], through
the activation of oncogene-induced senescence [21,22]. Specifi-
cally, we used mice carrying the above-mentioned OHT-inducible
endogenous K-RasV12 allele [31]. The oncogenic allele is linked
to a LacZ reporter that allows detection of those cells in which the
oncogene has been activated by Cre-mediated excision upon
OHT. For simplicity, we will refer to these mice as ‘‘K-RasV12
mice’’. In the following paragraphs, we describe separately the
phenotype of Atm-heterozygous and Atm-nullizygous mice when
combined with the K-RasV12 allele activated by OHT at 1 month
of age.
Regarding Atm-null mice, these mice succumb to thymic
lymphomas at an early age [3–5] and we observed that the
presence or absence of the K-RasV12 allele did not affect survival
in an Atm-null context (Fig. 2A). Examination of moribund Atm-
null mice indicated that all of them, with or without K-RasV12,
developed thymic lymphomas with similar histopathological
characteristics (not shown). All the thymic lymphomas (n=5)
examined from K-RasV12/Atm-null animals were positive for
LacZ (Supplementary Fig. S2; note that this staining is at pH 7
and does not produce cross-staining with senescence-associated b-
galactosidase, which is measured at pH 6). The above is an
interesting observation because expression of the K-RasV12
oncogene was achieved in ,8% of the cells of the thymus
(quantified in scanned photographs; see example in Supplemen-
tary Fig. S2). These observations suggest that those thymocytes
carrying the activated oncogene have a selective advantage
compared to the non-oncogenic ones. We conclude that K-
RasV12 has a modest impact on thymic lymphomagenesis driven
by Atm-loss, providing a selective advantage to the tumoral cells,
but without accelerating tumor onset.
In agreement with previous results [31], oncogenic activation of
K-Ras in 1-month old mice led to lung carcinogenesis with full
penetrance and death between 9 and 16 months of age.
Unexpectedly, Atm-heterozygosity did not diminish significantly
the survival of K-RasV12 mice when compared with their control
Atm wild-type mice (Fig. 2A; logrank test p=0.79) and histopath-
ological analyses confirmed that death was due to the presence of
multiple lung tumors.
Despite the previous negative data using Atm-heterozygous
mice, we reasoned that the role of Atm in K-RasV12-driven lung
tumorigenesis could perhaps be revealed in mice completely
deficient in Atm. For this, we sacrificed Atm-null and Atm-wt mice
carrying the activated K-RasV12 allele at 5 months of age
(4 months post-activation with OHT), when most Atm-null mice
had not developed yet frank lymphomas but lung tumors were
already present. Tumors were counted and grouped in 4 grades,
from adenomas (G1–G3) to adenocarcinomas (G4), according to
the classification of Johnson et al. [35]. Quantification of the
number of lesions indicated that the status of Atm had no
significant impact on tumor incidence (Atm-wt: 8.1 lesions/mouse;
Atm-null: 7.2 lesions/mouse; n=15 per genotype). Interestingly,
histopathological analysis of more than 100 lesions per genotype
revealed that Atm-nullizygosity had a modest, albeit significant,
effect on tumor progression (Fig. 2B). This effect was restricted to
the pre-malignant stages with a ,50% decrease in G1 adenomas
and a ,50% increase in G3 adenomas in Atm-null mice compared
to their wt controls. At this time of analysis (5 months of age), no
significant differences were observed in the incidence of malignant
tumors (G4, adenocarcinoma) (Fig. 2B).
Next, we wondered whether, despite the modest effect of Atm-
deficiency on tumor progression, lung adenomas in Atm-null mice
had lost the senescence response characteristic of these tumors
[37]. Senescence was evaluated by the widely accepted marker
senescence-associated b-galactosidase (SAbGal; [38]). Remark-
Figure 2. Limited role of Atm in Ras-driven murine lung
tumorigenesis. A. Kaplan-Meier survival curves of the indicated mice
(n=15 mice for each group). The inducible K-RasV12 allele was
activated with OHT when the mice were 1 month old. B. Quantification
of the different grades of lesions found in the lungs of K-RasV12/Atm-wt
and K-RasV12/Atm-null mice (15 mice per group, and a total of n=121
and n=108 lesions, respectively). Asterisks indicate statistical signifi-
cance of the Fisher’s test p,0.05.
doi:10.1371/journal.pone.0005475.g002
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comparable to Atm-wt adenomas (Fig. 3A; for whole lung
panoramic views see Supplementary Fig. S3). As previously
reported [37], adenocarcinomas were negative for SAbGal (see
example in Supplementary Fig. S3). Moreover, Atm-null adenomas
had the same proliferative index as Atm-wt adenomas (Fig. 3B),
thus indicating that Atm is not a barrier for the proliferation of
these pre-malignant lesions (apoptosis was essentially undetectable
in these lesions, not shown). These negative data prompted us to
evaluate whether the K-RasV12-driven adenomas had an ongoing
DNA damage response, however, we were unable to detect
cH2AX positive cells in the adenomas (Fig. 3C). Finally, as an
additional control, induction of the senescence mediator Arf was
readily detected in lung adenomas, but not in carcinomas (Fig. 3D),
further reinforcing the idea that oncogene-induced senescence in
this model occurs in the absence of DNA damage signaling.
Collectively, we conclude from the above data that senescence
at the pre-malignant stages of K-RasV12-driven lung tumorigen-
esis is not associated to a detectable DNA damage response and it
is independent of the status of Atm. Accordingly, the absence of Atm
has a modest impact on the pre-malignant stages of this
tumorigenesis model. It is conceivable that loss of function of
Atm could increase aggressiveness at later stages of tumorigenesis.
Limited role of Atm in protection from chemically-
induced fibrosarcomas
To further evaluate the roleof Atm in a cancer model initiated by
DNA damage and under a strong control by p53-mediated tumor
suppression, we performed chemical carcinogenesis with the DNA
damaging agent 3-methyl-cholanthrene (3MC). This carcinogen
generates fibrosarcomas when injected intramuscularly in mice, and
tumors carry frequent oncogenic mutations in K-Ras or N-Ras
[28,39–41], together with a high incidence of p53 inactivation by
deletion or point mutation [41,42]. Confirming the relevant role of
p53 in the control of these tumors, we have previously shown that
the latency of 3MC-fibrosarcomas is highly sensitive to the activity
of p53. In particular, mice carrying three functional alleles of the
p53 gene (p53-super) have a 50% increase in p53 gene dosage
relative to wild-type mice (p53-wt), and this increase in p53 activity
translates into a significant delay in the latency of 3MC-
fibrosarcomas [43]. To evaluate the role of Atm in this in vivo assay
of p53-mediated tumor suppression, we performed the appropriate
crosses to compare p53-wt and p53-super in an Atm-null
background. As validation of our genetic system, we observed that
the short-term response of p53 to acute DNA damage (3h post-
irradiation) was abrogated in the absence of Atm, regardless of the
p53 gene dose; and, in the presence of Atm, the levels of p53 and p21
were directly associated to the p53 gene dose (Supplementary Fig.
S4). However, unexpectedly, the status of Atm did not affect the
latency of 3MC-fibrosarcomas neither in a p53-wt context nor in a
p53-super context (Fig. 4A; statistical analyses indicated in the
legend). The lack of effect of Atm is in contrast to the dramatic effect
of Arf, whose deficiency completely abrogates p53-mediated tumor
suppression in this cancer model without affecting the short-term
response to DNA damage [28] (see also Fig. 4A). Tumors from all
the genotypes (n=5 per genotype) were characterized histologically
and all of them showed a strong constitutive DNA damage response
(,50% of cells positive for cH2AX), a high mitotic index (,50% of
cellspositiveforKi67),andvery lowapoptosis(,1%ofcellspositive
for activated caspase-3) (Fig. 4B). Quantification of these markers
indicated that their prevalence was not affected by the status of Atm
(Fig. 4B). The presence of high levels of cH2AX in Atm-null tumors
indicates that other kinases from the Atm family are responsible for
the phosphorylation of H2AX, such as Atr or Dnapk. Of note,
tumors arising in Arf-null mice or in p53-super mice showed a
modest, albeit significant, decrease in the number of cH2AX-
positive cells (Fig. 4B).
We wondered whether Atm-nullizygosity, despite its lack of effect
on tumor latency, could relieve the selective pressure to inactivate
p53. For this, we examined the functional status of p53 in 3MC-
fibrosarcomas and in cell lines derived from these tumors.
Inactivation of p53 by point mutation generally renders p53
abnormally stable and readily detectable by immunohistochemis-
try, and results in undetectable levels of the p53-target p21. The
large majority of 3MC-fibrosarcomas produced in Atm-wt mice
(19/22=86%, after combining p53-wt and p53-super) had an
immunohistochemical profile consistent a ‘‘p53 mutant’’ pattern
(i.e. p53-strongly positive & p21-negative; Table 1, see example in
Fig. 5A), thus confirming the strong pressure to inactivate p53 in
this cancer model. Importantly, a similar situation was observed in
the 3MC-fibrosarcomas generated in Atm-null mice, where the
majority (14/18=78%) also had a ‘‘p53-mutant’’ pattern,
including those generated in a p53-super context (Table 1 and
Fig. 5A). In contrast to this and in agreement with our previous
data [44], tumors generated in Arf-null mice presented a ‘‘p53
functional’’ staining pattern (i.e. p53-weakly positive & p21-
positive; Table 1, Fig. 5A and see Supplementary Fig. S5 for a
nutlin-sensitivity assay), thus confirming that Arf-deficiency, in
contrast to Atm-deficiency, completely relieves the pressure to
inactivate p53.
To further substantiate the above observations, we examined
the functionality of p53. The cancer cell lines derived from wt or
Atm-null mice had constitutively high levels of p53 and essentially
undetectable levels of p21 both before and after ionizing radiation
(Fig. 5B, lanes 1–10), compatible with a mutant p53 status. We
wondered whether the 3MC-fibrosarcomas produced in wt mice
retained a normal response to DNA damage. As shown in Fig. 5B,
the phosphorylation of Chk2, Atm and H2AX shortly after
ionizing radiation was normal in representative lines from wt mice
(lanes 1,2,7–10) but, as expected, Chk2 phosphorylation was
absent in the fibrosarcomas from Atm-null mice (lanes 3–6).
Therefore, 3MC-fibrosarcomas derived from wild-type mice retain
an apparently functional Atm and DNA damage response, and
Atm-deficiency does not relieve the pressure to inactivate p53. The
cancer cell lines derived from Arf-null mice also had a normal
DNA damage response (Fig. 5B, lanes 11–14), but in sharp
contrast with those fibrosarcomas from wt or Atm-null mice, Arf-
null fibrosarcomas conserved a functional p53/p21 response to
DNA damage (lanes 11–14).
Finally, to seek evidence for an impact of Atm-deficiency in this
cancer model, we examined the level of genomic instability in the
different 3MC-fibrosarcoma cell lines described above. Consistent
with the well-established role of p53 in genomic stability, those
fibrosarcomas lacking functional p53 had high levels of chromo-
somal fusions (Table 2). To dissociate the impact of p53 and Atm
on genomic stability, we grouped the Atm-null cancer cell lines into
those with mutant p53 and those with functional p53 (treatment
with the MDM2 inhibitor nutlin confirmed the presence or
absence of functional p53, see Supplementary Fig. S6). Interest-
ingly, cancer cells deficient in Atm, but not in p53, had
significantly higher levels of chromosomal instability, particularly
fusions and aneuploidies, than the comparable Arf-null;p53-
functional cells (Table 2). In summary, these observations indicate
that the absence of Atm increases genomic instability, but it does
not relieve the pressure to inactivate p53 during cancer
development.
Collectively, we conclude that Atm plays a minor role in 3MC
carcinogenesis. In the absence of Atm, genomic instability is
Tumor Suppression by ATM
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5475Figure 3. Lack of evidence for DNA damage signaling and limited role of Atm in senescent murine lung tumors. A. Representative
stainings of senescence-associated b2galactosidase (SAbGal) in lung cryosections from K-RasV12/Atm-wt and K-RasV12/Atm-null mice. The grade of
the tumor (G2 or G3) is indicated. See Supplementary Fig. S3 for panoramic views, including adenocarcinomas (G4, which are negative for SAbGal). B.
Examples of Ki67 stainings of lung adenomas from the indicated mouse genotypes and quantification (adenomas n=4 for each genotype). Values
correspond to the average and standard deviation. C. Lack of detectable cH2AX staining in K-RasV12-driven lung adenomas. The bottom panel
shows a positive control of the lung from an irradiated wildt-type mouse (5 Gy, 45 min post-IR). D. Expression of Arf during K-RasV12-driven lung
tumorigenesis is specifically associated to the pre-malignant stages (adenomas, top), but not to the malignant ones (adenocarcinomas, bottom). Note
that some cells in the adenoma are Arf-positive and others are Arf-negative, consistent with the concept that not all the tumor cells of these lesions
are senescent, and indeed a fraction of cells are proliferating, as shown in part B.
doi:10.1371/journal.pone.0005475.g003
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PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5475Figure 4. Limited role of Atm in p53-mediated tumor suppression and DNA damage response in chemically-induced fibrosarcomas.
A. Mice of the indicated genotypes, wt (n=15), p53-super (n=16), Atm-null (n=9), p53-super/Atm-null (n=13) and Arf-null (n=12), were injected
intramuscularly with 3-methyl-cholanthrene (3MC) and tumour development was monitored. Kaplan-Meier tumour-free curves were obtained and
statistical significant differences (logrank test) were found for wt vs. p53-super (p,0.005), Atm-null vs. p53-super/Atm-null (p,0.001) and Arf-null vs.
wt (p,0.0001). No significant differences were found for wt vs. Atm-null (p=0.11), or p53-super vs. p53-super/Atm-null (p=0.18). B. Quantification of
Tumor Suppression by ATM
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tumor suppression are affected.
Discussion
The role of ATM in tumor suppression is solidly established and
attributed, at least in part, to its well-known function in DNA
damage repair. In addition to its function in guarding the genome,
ATM has been recently proposed to act as a general tumor
suppressor through its ability to activate p53 in response to
oncogenic stress and the subsequent induction of oncogene-induced
cellular senescence [17,18]. This model is mainly based on human
cultured fibroblasts where ATM plays an essential role in oncogene-
induced senescence [21–23]. In this work, we have attempted to
find in vivo supporting evidence for the role of ATM in p53-
dependent tumor suppression and in oncogene-induced senescence
using murine experimental systems, namely, Ras-induced senes-
cence in mouse embryo fibroblasts (MEFs), Ras-induced senescence
during lung tumorigenesis, and chemically-induced fibrosarcomas.
A first unexpected observation was the absence of a detectable
DNA damage response upon ectopic overexpression of oncogenic
H-Ras in MEFs, under conditions that resulted in upregulation of
Arf, stabilization of p53, and acquisition of a fully senescent
morphology. Given the absence of a detectable DNA damage
response elicited by oncogenic H-Ras, it was not surprising that
the stabilization of p53 in response to the oncogene was not
affected by the absence of Atm. Conceptually similar observations
were made in a more physiological model of oncogene-induced
senescence in which an inducible endogenous K-RasV12 allele
drives the development of adenomas (pre-malignant) and adeno-
carcinomas (malignant), being characterized the adenomas by a
strong senescence response [37]. Again, as in the case of MEFs, we
could not detect evidence of persistent DNA damage signaling in
the K-RasV12-driven adenomas, which were invariably senescent
as shown in [37] (Fig. 3C). Consistently with this, Atm deficiency
did not ablate the senescent response characteristically present in
lung adenomas. Interestingly, however, the absence of Atm had a
modest, albeit significant, effect in the degree of progression of
adenomas. In contrast to these data, ablation of Arf strongly
accelerates lung tumorigenesis driven by oncogenic K-RasV12
[45], and it eliminates oncogenic Ras-induced senescence during
mammary tumorigenesis [29,30]. Together, these results indicate
that oncogene-induced senescence in murine fibroblasts and lung
epithelial cells is not associated to an ongoing DNA damage
response and, therefore, activation of p53 and establishment of
senescence occur independently of Atm.
Based on the above data, we focused on a murine cancer model
initiated by a DNA damage agent (3-methyl-cholanthrene or
3MC), known to be highly sensitive to the activity of p53 [43], and
accompanied by a persistent DNA damage response (see Fig. 4B).
However, the absence of Atm did not impact on the kinetics of
tumor development, even under conditions able to detect a 1.5-
fold difference in p53 activity. Histopathological analyses of these
tumors indicated that the absence of Atm did not decrease the
persistent DNA damage response, which must be signaled by other
kinases of the Atm family, such as Atr or Dnapk. Importantly, the
absence of Atm did not relieve the strong selective pressure to
inactivate p53, further confirming that the tumor suppressor
activity of p53 in this cancer model is not regulated by Atm. These
results are in agreement with previous reports that also failed to
detect an impact of Atm on p53-mediated tumor suppression in
murine brain and skin cancers [46,47]. The absence of effect of
Atm on p53-dependent tumor suppression is in sharp contrast with
a number of reports where the absence of Arf essentially eliminates
p53-mediated tumor suppression and completely alleviates the
selective pressure to inactivate p53 in lymphomas, sarcomas and
skin tumors [26–28,48,49]. Moreover, the 3MC-fibrosarcomas
originated in Arf-null mice retained a functional response to DNA
damage, as judged by the phosphorylation of Atm and H2AX, as
well as, by the stabilization of p53 and the induction of p21 upon
irradiation (Fig. 5B). In summary, in this cancer model initiated by
a DNA damage agent and associated to persistent DNA damage,
the absence of Atm does not have a detectable effect on DNA
damage signaling or on p53-dependent tumor suppression. Finally,
and interestingly, we found that Atm-null fibrosarcomas were
characterized by high levels of chromosomal instability (Table 2),
thus testifying to the known role of Atm in genome stability.
It is critically important to emphasize that our data do not
negate a tumor suppressor role for ATM, which is solidly
established both in human and mice (see Introduction), but
question the generality of the model proposed for ATM as a
critical mediator of p53-activation and senescence in response to
oncogenic signaling [17,18]. This model is mainly based on the
behavior of human fibroblasts in vitro and it does not seem to apply
to the three murine experimental systems analyzed here, namely,
oncogene-induced senescence in fibroblasts and during lung
tumorigenesis, and p53-mediated tumor suppression during
carcinogenesis initiated by a DNA damage agent. By large, the
molecular biology of human and murine cancer seem to follow the
same mechanistic paradigms, however, it is conceivable that ATM
is an exceptional case playing a major tumor suppression role in
human cancer, but not in murine cancer.
Materials and Methods
Ethics statement
Mice were treated in accordance with the Spanish Laws and the
Guidelines for Humane Endpoints for Animals Used in Biomed-
ical Research.
the persistent DNA damage response (cH2AX), proliferation (Ki67), and apoptosis (activated caspase-3) in 3MC-fibrosarcomas generated in mice of
the indicated genotypes. Quantifications are relative to the 3MC-fibrosarcomas in wild-type mice. Values correspond to the average and standard
deviation (n=5 per genotype). Examples of the immunostainings are shown in the panels at the right.
doi:10.1371/journal.pone.0005475.g004
Table 1. Immunohistochemical analysis of 3MC-
fibrosarcomas.
Genotype
ARF
positive
p53 positive
(mutant p53)
a
p21 positive
(active p53)
a
Atm-wt;p53-wt 10/10 9/10 1/10
Atm-wt;p53-super 12/12 10/12 1/12
Atm-null;p53-wt 7/7 7/7 0/7
Atm-null;p53-super 8/11
b 7/11 3/11
Arf-null n.a. 1/9 7/9
aMost tumors strongly positive for p53, lacked p21 expression (reflecting a non-
functional mutant p53); and, tumors negative or weakly positive for p53, had
detectable p21 (reflecting a functional p53)
bThe few tumors that lacked Arf were negative or weakly positive for p53
(reflecting a functional p53)
doi:10.1371/journal.pone.0005475.t001
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K-RasV12;Atm-null mice were obtained by crossing transgenic
mice carrying a tamoxifen-inducible Cre and a Cre-inducible K-
RasV12 endogeneous allele [31] with Atm-null mice [4]. Activation
of the Cre-inducible K-RasV12 was performed in 1-month old
mice by injection of tamoxifen as previously described [31]. Arf-
null mice [50] and p53-null mice [51] were previously described.
Mice were housed under standard conditions at the serum-
pathogen free facility of the Spanish National Cancer Research
Centre (CNIO). Upon signs of morbidity or when required, mice
were euthanized. Mouse embryo fibroblasts (MEFs) were obtained
from E13.5 embryos as previously described [52] and grown in
Dulbecco’s Minimum Essential Media (DMEM, Invitrogen,
Grand Island, NY, USA) supplemented with 10% FBS (Hyclone,
Logan, UT). MEFs were grown in 3% oxygen to minimize
premature senescence of Atm-deficient cells. In all experiments
with MEFs, low passage (less than 3 passages) MEFs were used.
Oncogene-induced senescence in MEFs
Cells were retrovirally transduced following standard proce-
dures using constructs based on the vector pBabe-puro (Fig. 1A) or
pLPC-puro (Fig. 1C and Suppl. Fig. S1) and expressing oncogenic
Figure 5. Absence of Atm does not relieve the selective pressure to inactivate p53 during chemical carcinogenesis. A. Representative
images of 3MC-fibrosarcomas immunostained for Arf, p53 and p21 (see also Table 1). The upper and middle rows are representative of the large
majority of fibrosarcomas developed in wild-type (upper) and Atm-null (middle) mice, which are consistent with a mutant p53 (i.e. strongly positive
for p53 and negative for p21). The lower row is representative of the fibrosarcomas developed in Arf-null mice, which are consistent with a functional
p53 (i.e. very weakly positive for p53 and positive for p21). B. Examples of cancer cell lines established from 3MC-fibrosarcomas (each line derives
from an independent fibrosarcoma). The genotype of the mice where the 3MC-fibrosarcomas were generated is indicated, as well as, the status of
p53 as determined by a nutlin-sensitivity assay (see Supplementary Figures S5 and S6). Cell lines were exposed to 10 Gy and protein extracts were
obtained 1h and 24h after irradiation. The levels of the indicated proteins were determined by immunoblotting using b-actin as loading control.
doi:10.1371/journal.pone.0005475.g005
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selected with 1.5 mg/ml puromycin for 2–3 days as described [54].
Cell extracts were prepared 6 days post-selection. MEFs carrying a
tamoxifen-inducible K-RasV12 allele were also used [31].
Quantification of DNA damage by quantitative immunofluores-
cence of single cells was performed as described [55]. Briefly, cells
were grown on mCLEAR-bottom 96-well dishes (Greiner Bio-One)
and analyzed on a BD Pathway 855 BioImager (Beckton
Dickinson). Image analysis was performed with the AttoVision
software (Beckton Dickinson). All the images for quantitative
analyses were acquired under nonsaturating exposure conditions.
Tumor induction and establishment of fibrosarcoma cell
lines
For fibrosarcomagenesis, 2–4 mo old animals were injected
intramuscularly in one of the rear legs with 1 mg of 3-methyl-
cholanthrene (Sigma) dissolved in corn oil, and tumor develop-
ment was followed, as previously described [43]. Mouse
fibrosarcoma cell lines were obtained from tumors as previously
described [43]. Briefly, the tumor mass was rinsed in phosphate-
buffered saline (PBS) with antibiotics and then minced with razor
blades into small pieces that were placed in 100-mm diameter
dishes in the presence of DMEM/10% FBS. Cell lines were
established from tumor outgrowths after four to six passages. Cells
were plated in 3.5-cm diameter plates and, the following day, were
irradiated with 10 Gy at 1.94 Gy/min in a Shepherd Mark 1–30
irradiator.
Metaphase analyses
Exponentially growing cells were incubated with 0.1 mg/ml
colcemide (Gibco, Invitrogen, Paisley, UK) for 2 h at 37uC and
then fixed in methanol:acetic acid (3:1). Metaphases were spread
in acetic acid 45%. Chromosome number, fragments and fusions
were analyzed in at least 50 metaphases per cell line.
Immunoblots and immunohistochemistry
Whole-cell protein extracts were obtained using RIPA buffer.
For immunoblotting, we used the following primary antibodies:
anti-p53 (NCL-p53-CM-5p, Novocastra; and 1C12, Cell Signaling
Technology), anti-p21 (p21-C-19-G, Santa Cruz Biotechnology),
anti-total-Atm (NB100-220, Novus Bio), anti-phospho-Ser1981-
Atm (Atmp1981, 200-301-400, Rockland Biochemicals), anti H-
Ras (clone 18, BD Biosciences), anti-Arf (Ab80-100, Abcam; and
5-C3-1, Santa Cruz Biotechnology), anti-Chk2 (05-649, clone 7,
Upstate), anti-phospho-Chk1 (2341, Cell Signaling Technology),
anti-cH2AX (05-636, Millipore), and anti-b-actin (clone AC-15,
Sigma). Protein levels were visualized after incubation with the
appropriate secondary antibodies conjugated with HRP followed
by detection with ECL Plus (Amersham) or conjugated with
fluorescein followed by detection with Oddysey (Li Cor
Biosiences).
For immunohistochemistry, formalin-fixed paraffin-embedded
tumor samples were incubated with the following antibodies: anti-
Ki67 (TEC-3, DAKO), anti-cH2AX (clone JBW301, Upstate),
anti-Caspase 3 active (R&D Systems), anti-Arf (5-C3-1, Santa
Cruz Biotechnology), anti-p53 (NCL-p53-CM-5p, Novocastra),
and anti-p21 (p21-C-19-G, Santa Cruz Biotechnology). For
quantification, 10 high power fields (406) were randomly chosen
under the microscope and the total number of positive cells was
counted for each tumor.
SA-b-Galactosidase activity. SA-b-Galactosidase activity
was evaluated using the ‘‘Senescence-bGal Staining Kit’’ (Cell
Signaling Technology) following the manufacturer’s instructions in
OCT-embedded lung sections. Stained slides were subsequently
stained with nuclear fast red.
Supporting Information
Figure S1 Atm-deficiency does not render MEFs permissive to
H-RasV12-driven proliferation A. Primary mouse embryo fibro-
blasts (MEFs) of the indicated genotypes were retrovirally
transduced with H-RasV12 and 2000 cells were seeded in 10-cm
diameter plates. After 2 weeks, cells were fixed and stained and
colonies were counted. All incubations were done in low oxygen
(3%). Top, quantification; bottom, representative plates. B. Same
as in A but after retroviral transduction of cells with oncoviral
protein E1a and H-RasV12.
Found at: doi:10.1371/journal.pone.0005475.s001 (0.34 MB TIF)
Figure S2 Expression of K-RasV12 provides a selective
advantage for T-lymphomagenesis in Atm-null mice. Left,
representative LacZ staining of the thymus 2 days after activation
of the K-RasV12 allele by tamoxifen (the oncogenic allele is linked
with an IRES to LacZ). Quantification indicates that approxi-
mately 8% of the cells are LacZ-positive. Right, representative
image of a thymic lymphoma from a K-RasV12;Atm-null mouse.
A total of 5 lymphomas were analyzed and all of them were
strongly positive for LacZ.
Found at: doi:10.1371/journal.pone.0005475.s002 (0.20 MB TIF)
Figure S3 In vivo senescence in K-RasV12-driven lung
adenomas is not affected by the status of Atm. Complete lung
Table 2. Chromosomal instability in 3MC-fibrosarcoma cell lines.
Genotype of
mouse Status of p53
a
Fusions (% of
chromosomes)
Aneuploidies (% of
metaphases)
c
Breaks (% of
chromosomes)
Metaphases analyzed (cell
lines analyzed)
Atm-wt mutant 1.262.4 56620 1.461.8 294 (5)
Atm-null mutant 2.4612.0 85622 14.0666.0 111 (2)
Atm-null
b functional 1.567.5
d 74634
d 1.967.5 109 (2)
Arf-null functional 0.0960.41
d 31613
d 1.066.0 287 (5)
aThe functional status of p53 in the fibrosarcoma cell lines was determined by examining the levels of p53 and p21 upon cIR, both by immunohistochemistry (Fig. 5A)
and immunoblotting (Fig. 5B), as well as, by their susceptibility to cell cycle arrest upon treatment with nutlin (Supplementary Fig. S5 and S6).
bThese Atm-null lines with functional p53 correspond to a minority of the 3MC-fibrosarcomas produced in Atm-null mice, which by large have mutant p53 (see Table 1
and Fig. 5B). Only two lines were obtained that retained functional p53 (Supplementary Fig. S6): one derived from an Atm-null;p53-super mouse and the other one
from an Atm-null;p53-wt mouse.
cAneuploidies correspond to metaphasases with chromosome numbers different from 4061o r8 0 62.
dStatistical comparison (t-test) between Atm-null(p53-functional) and Arf-null(p53-functional): metaphases with fusions, p=0.04; aneuploid cell lines, p=0.06.
doi:10.1371/journal.pone.0005475.t002
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galactosidase (SAbGal) and nuclear fast red. Slides were examined
blindly by an expert pathologist, Dr. Marta Can ˜amero (CNIO),
who determined the grade of the tumors. All the adenomas (grades
G1 to G3) were positive for SAbGal. The lung in the right side
contains an adenocarcinoma that is shown at high magnification
below. Adenocarcinomas (grade 4) presented a very weak SAbGal
staining.
Found at: doi:10.1371/journal.pone.0005475.s003 (0.43 MB TIF)
Figure S4 The short-term response of the lung to DNA damage
is eliminated in the absence of Atm and it is enhanced in the
presence of an extra allele of p53. Mice of the indicated genotypes
were irradiated and protein extracts were prepared from their
lungs 3 h post-IR. The antibody used for phospho-Ser18-p53 was
from Cell Signaling (#9284S).
Found at: doi:10.1371/journal.pone.0005475.s004 (0.12 MB TIF)
Figure S5 Arf-deficiency relieves the selective pressure to
inactivate p53 in 3MC-fibrosarcomas (nutlin-sensitivity assay).
Fibrosarcoma cell lines obtained from the wt or Arf-null mice were
treated with 10 mM of the active enantiomer of nutlin (nutlin-3a,
N3a) or with the inactive enantiomer (nutlin-3b, N3b). Nutlin
activates p53 by inhibiting MDM2. After 48 h, cells were fixed
and the proportion of S-phase cells was determined by flow
cytometry. All the fibrosarcoma cell lines derived from wt mice did
not respond to N3b, thus indicating that p53 was not functional; in
contrast, all but one cell lines derived from Arf-null mice
responded to N3b by strongly decreasing proliferation.
Found at: doi:10.1371/journal.pone.0005475.s005 (0.07 MB TIF)
Figure S6 Identification of Atm-null fibrosarcoma cell lines
retaining functional p53 (nutlin-sensitivity assay). The large
majority of 3MC-fibrosarcomas from Atm-null mice lacked
functional p53 (see Table 1), however, two Atm-null cell lines
were identified that retained a functional p53. These cell lines, #2
and #3 in the figure, responded to 10 mM nutlin (racemic
mixture) by undergoing cell cycle arrest as measured by flow
cytometry 48 h after treatment.
Found at: doi:10.1371/journal.pone.0005475.s006 (0.06 MB TIF)
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